Detalles de la búsqueda
1.
Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Drug Metab Dispos
; 48(3): 217-229, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31911485
2.
Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Biopharm Drug Dispos
; 35(9): 543-52, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25264242
3.
Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
Drug Metab Dispos
; 41(4): 727-34, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23298863
4.
The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.
Br J Clin Pharmacol
; 72(5): 775-86, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21545481
5.
Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
Biopharm Drug Dispos
; 30(4): 163-84, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19544287
6.
Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
Drug Metab Dispos
; 36(12): 2564-70, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18787054
7.
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
Clin Pharmacokinet
; 41(6): 445-52, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12074692
8.
Shift in pH of biological fluids during storage and processing: effect on bioanalysis.
J Pharm Biomed Anal
; 32(3): 513-22, 2003 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-14565556
9.
Dose schedule optimization and the pharmacokinetic driver of neutropenia.
PLoS One
; 9(10): e109892, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25360756
10.
Growth rate analysis and efficient experimental design for tumor xenograft studies.
Cancer Inform
; 13(Suppl 4): 65-72, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25574127
11.
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Drug Metab Lett
; 7(2): 96-104, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24484538
12.
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Mol Cancer Ther
; 13(9): 2170-83, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24980948
13.
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Cancer Chemother Pharmacol
; 72(6): 1255-64, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24101146
14.
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Adv Ther
; 29(2): 163-77, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22271159
15.
Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.
Drug Metab Dispos
; 35(5): 795-805, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17303626
16.
Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Drug Metab Dispos
; 35(1): 150-67, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17062777
Resultados
1 -
16
de 16
1
Próxima >
>>